Samar Hafida , MD
Staff Endocrinologist/ Adult Diabetes ,weight management and clinical nutrition specialist
Assistant Medical Director, Global Education & Care
Clinical Instructor Harvard School of Medicine
Joslin Diabetes Center
One Boston Place
Boston, MA 02215
Tel: (617) 309-2665
Fax: ((617) 309-2734
Shesha Desai. Pharm D. Rph.BC-ADM | Diabetes Program Coordinator/ Staff Pharmacist / ADR Coordinator Phone: 609-249-7509, 609-584-6575 | Fax: 609-584-6745 | Shesha.Desai@rwjbh.org
NOTICE: This e-mail and its attachments, if any, may contain legally privileged and/or confidential information protected by law. It is intended only for use by the named addressee(s). If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this e-mail and its attachments, if any, is strictly prohibited. If you have received this transmission in error, please immediately notify the sender by telephone or by reply e-mail, and permanently delete this e-mail and the attachments, if any, and destroy any printouts.
Shesha Desai. Pharm D. Rph.BC-ADM | Diabetes Program Coordinator/ Staff Pharmacist / ADR Coordinator Phone: 609-249-7509, 609-584-6575 | Fax: 609-584-6745 | Shesha.Desai@rwjbh.org">hesha.Desai@rwjbh.org
I would just caution that if you are already using U-500 pens or U-500 syringes, there's no need to multiply the dose by 5.In our hospital, we have kept it on formulary despite low use. Maybe 1-2 patients per month, but often these patients really need it. We use vials to control cost (instead of single-patient use pens) and U500 syringes. The dose is drawn by pharmacy. We have shown this process to be safer. It also requires an Endocrinology consult.Deal EN, Tobin GS. Policy implementation for inpatient management of U-500 insulin resulting in lower incidence of hypoglycemia. Endocr Pract. 2011 May-Jun;17(3):521. PMID: 21700563.